Inscripción
profesionales sanitarios
para pacientes y familiares
FDA Approves Dual-Targeted Therapy for Head and Neck Cancer
FDA Approves Dual-Targeted Therapy for Head and Neck Cancer
Overall response rate was 42% in a population with limited treatment options
www.medpagetoday.com
Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update | Journal of Clinical Oncology
Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update
PURPOSETo update the 2021 CSCO-ASCO guideline on chemotherapy in combination with radiotherapy for the definitive treatm...
ascopubs.org
Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline | Journal of Clinical Oncology
Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline
PURPOSETo provide evidence-based recommendations on first- and subsequent-line systemic therapy, maintenance therapy, locoregi...
ascopubs.org
FDA Approves Dual-Targeted Therapy for Head and Neck Cancer
FDA Approves Dual-Targeted Therapy for Head and Neck Cancer
Overall response rate was 42% in a population with limited treatment options
www.medpagetoday.com
Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update | Journal of Clinical Oncology
Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update
PURPOSETo update the 2021 CSCO-ASCO guideline on chemotherapy in combination with radiotherapy for the definitive treatm...
ascopubs.org
Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline | Journal of Clinical Oncology
Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline
PURPOSETo provide evidence-based recommendations on first- and subsequent-line systemic therapy, maintenance therapy, locoregi...
ascopubs.org
FDA Approves Dual-Targeted Therapy for Head and Neck Cancer
FDA Approves Dual-Targeted Therapy for Head and Neck Cancer
Overall response rate was 42% in a population with limited treatment options
www.medpagetoday.com
Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update | Journal of Clinical Oncology
Treatment of Stage IB to III Nasopharyngeal Carcinoma: CSCO-ASCO Guideline Update
PURPOSETo update the 2021 CSCO-ASCO guideline on chemotherapy in combination with radiotherapy for the definitive treatm...
ascopubs.org
Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline | Journal of Clinical Oncology
Treatment of Recurrent and/or Metastatic Nasopharyngeal Carcinoma: CSCO and ASCO Joint Guideline
PURPOSETo provide evidence-based recommendations on first- and subsequent-line systemic therapy, maintenance therapy, locoregi...
ascopubs.org
TTCC en cifras
